ROUND TABLE

JOP. J Pancreas (Online) 2007; 8(4 Suppl.):488-494.

Action of Antiproteases on the Inflammatory Response in Acute Pancreatitis

Chun-Chia Chen, Sun-Sang Wang, Fa-Yauh Lee

Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine. Taipei, Taiwan

Summary

The spectrum of acute pancreatitis ranges from mild edematous disease to a severe necrotizing process which is usually accompanied by local or systemic complications and even mortality. Early deaths (within the first week) due to severe acute pancreatitis are generally caused by massive inflammatory responses which result in multiple organ failure. Although the exact mechanisms which trigger the inflammatory and necrotizing processes are not completely understood, it is generally accepted that autodigestion and activated leukocytes play important roles in the pathogenesis of acute pancreatitis. Proinflammatory cytokines are associated with systemic inflammatory response syndrome and multiple organ failure syndrome in acute pancreatitis. A compensatory anti-inflammatory response occurs in parallel with systemic inflammatory response syndrome. Trypsin secreted by the pancreatic acinar cells activates protease-activated receptor-2 which can result in the production of cytokines. Protease inhibitors such as aprotinin, gabexate mesilate, nafamostat mesilate, ulinastatin, etc. can inhibit the various enzymes and inflammatory response in experimental and clinical studies. Thus, protease inhibitors have been considered as a potential treatment to inhibit the pancreatic inflammation in acute pancreatitis. The beneficial effects of antiproteases on experimental severe acute pancreatitis may be, in part, due to the modulation of inflammatory cytokine responses. The effect of protease inhibitors on the inflammatory response in human acute pancreatitis deserves further study.

Full text: HTML format  PDF format
  Look up who cited this article

References

  1. Banks PA. Acute pancreatitis: medical and surgical management. Am J Gastroenterol 1994; 89:S78-85. [More details]

  2. Granger J, Remick D. Acute pancreatitis: models, markers, and mediators. Shock 2005; 24:45-51. [More details]

  3. Saluja AK, Steer ML. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion 1999; 60:27-33. [More details]

  4. Ohnishi H, Kosuzume H, Ashida Y, Kato K, Honjo I. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sci 1984; 29:26-32. [More details]

  5. Wisner JR Jr, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas 1987; 2:181-6. [More details]

  6. Suzuki M, Isaji S, Stanten R, Frey CF, Ruebner B. Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice. Int J Pancreatol 1992; 11:59-65. [More details]

  7. Dabrowski A, Gabryelewicz A. The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. J Physiol Pharmacol 1994; 45:455-65. [More details]

  8. Chen HM, Shyr MH, Chen MF. Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis. J Formos Med Assoc 1997; 96:704-9. [More details]

  9. Hartwig W, Werner J, Jimenez RE, Z'graggen K, Weimann J, Lewandrowski KB, et al. Trypsin and activation of circulating trypsinogen contribute to pancreatitis-associated lung injury. Am J Physiol 1999; 277:G1008-16. [More details]

  10. Chen CC, Wang SS, Tsay SH, Lee FY, Lu RH, Chang FY, Lee SD. Effects of gabexate mesilate on serum inflammatory cytokines in rats with acute necrotizing pancreatitis. Cytokine 2006; 33:95-9. [More details]

  11. Goebell H. Multicenter double-blind study of gabexate mesilate (Foy) given intravenously in low dose in acute pancreatitis. Digestion 1988; 40:83. [More details]

  12. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993; 14:117-24. [More details]

  13. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104:1165-70. [More details]

  14. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate (Foy) in the treatment of acute pancreatitis. Pancreas 1987; 6:698-700. [More details]

  15. Valderrama R, Perez-Mateo M, Navarro S, Vazquez N, Sanjose L, Adrian MJ, Estruch J. Multicenter double-blind trial of gabexate mesilate (FOY) in unselected patients with acute pancreatitis. Digestion 1992; 51:65-70. [More details]

  16. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy. Italian Group. N Engl J Med 1996; 335:919-23. [More details]

  17. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2:713-8. [More details]

  18. Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, Annese V. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65:624-32. [More details]

  19. Gross V, Leser HG, Heinisch A, Scholmerich J. Inflammatory mediators and cytokines - new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993; 40:522-30. [More details]

  20. Hirota M, Ohmuraya M, Baba H. The role of trypsin, trypsin inhibitor, and trypsin receptor in the onset and aggravation of pancreatitis. J Gastroenterol 2006; 41:832-6. [More details]

  21. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002; 9:401-10. [More details]

  22. Rinderknecht H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation? Int J Pancreatol 1988; 3:105-12. [More details]

  23. Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, et al. Elevation of serum interleukin-6 concentration precedes acute phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 101:782-5. [More details]

  24. Chen CC, Wang SS, Lee FY, Chang FY, Lee SD. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol 1999; 94:213-8. [More details]

  25. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000; 190:117-25. [More details]

  26. Chen CC, Wang SS, Lu RH, Chang FY, Lee SD. Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis. Gut 1999; 45:895-9. [More details]

  27. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000; 47:546-52. [More details]

  28. Chen CC, Wang SS, Lu RH, Lu CC, Chang FY, Lee SD. Early changes of serum proinflammatory and anti-inflammatory cytokines after endoscopic retrograde cholangiopancreatography. Pancreas 2003; 26:375-80. [More details]

  29. Rettally CA, Skarda S, Garza MA, Schenker S. The usefulness of laboratory tests in the early assessment of severity of acute pancreatitis. Crit Rev Clin Lab Sci 2003; 40:117-49. [More details]

  30. Chen CC. Serum markers in the early assessment of severity of acute pancreatitis: Which is the most useful? J Chin Med Assoc 2004; 67:439-41. [More details]

  31. Haberland G, McConn R. A rationale for the therapeutic action of aprotinin. Fed Proc 1979; 38:2760-7. [More details]

  32. Lasson A, Ohlsson K. Protease inhibitors in acute human pancreatitis. Correlation between biochemical changes and clinical course. Scand J Gastroenterol 1984; 19: 779-86. [More details]

  33. Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974; 61:177-82. [More details]

  34. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978; 65:337-41. [More details]

  35. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980; 21:334-9. [More details]

  36. Watanabe S. Acute pancreatitis: overview of medical aspects. Pancreas 1998; 16:307-11. [More details]

  37. Ino Y, Suzuki K, Sato T, Iwaki M. Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro. Nippon Yakurigaku Zasshi 1986; 88:449-55. [More details]

  38. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol 1986; 41:155-62. [More details]

  39. Waxler B, Rabito SF. Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors. Curr Pharm Des 2003; 9:777-87. [More details]

  40. Day JR, Taylor KM, Lidington EA, Mason JC, Haskard DO, Randi AM, Landis RC. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 2006; 131:21-7. [More details]

  41. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996; 83:696-700. [More details]

  42. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110:1658-62. [More details]

  43. Siebeck M, Fink E, Weipert J, Jochum M, Fritz H, Spannagl M, et al. Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock. J Trauma 1993; 34:193-8. [More details]

  44. Yuksel M, Okajima K, Uchiba M, Okabe H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J Pharmacol Exp Ther 2003; 305:298-305. [More details]

  45. Luh SP, Tsai CC, Shau WY, Chen JS, Kuo SH, Lin-Shiau SY, Lee YC. Effects of gabexate mesilate (FOY) on ischemia-reperfusion-induced acute lung injury in dogs. J Surg Res 1999; 87:152-63. [More details]

  46. Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg 1999; 177:78-82. [More details]

  47. Sugita H, Ishiko T, Ikei S, Hirota M, Ogawa M. FUT-175 inhibits the production of IL-6 and IL-8 in human monocytes. Res Commun Mol Pathol Pharmacol 1999; 103:57-64. [More details]

  48. Miyaso H, Morimoto Y, Ozaki M, Haga S, Shinoura S, Choda Y, et al. Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells. Dig Dis Sci 2006; 51:2007-12. [More details]

  49. Chen CL, Wang SD, Zeng ZY, Lin KJ, Kao ST, Tani T, et al. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 2006; 118:105-12. [More details]

  50. Endo S, Inada K, Yamashita H, Takakuwa T, Nakae H, Yamada Y, et al. The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8. Res Commun Chem Pathol Pharmacol 1993; 82:27-34. [More details]

  51. Ambiru S, Miyazaki M, Sasada K, Ito H, Kimura F, Nakagawa K, et al. Effects of perioperative protease inhibitor on inflammatory cytokines and acute-phase proteins in patients with hepatic resection. Dig Surg 2000; 17:337-43. [More details]

  52. Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006; 34:1351-7. [More details]

  53. Sun JL, Zhang XQ, Yu ZG, Ma R, Dai Y, Fan ZY, Sun JZ. Effects of ulinastatin on postoperative systemic inflammatory response of recipients of rat small bowel transplantation. Transplant Proc 2006; 38:1803-4. [More details]

  54. Pezzilli R, Barakat B, Morselli-Labate AM. Evaluation of the immunomodulatory effect of gabexate mesilate in patients with severe acute pancreatitis. Curr Ther Res 1998; 59:710-6. [More details]

  55. Mikami Y, Takeda K, Matsuda K, Qiu-Feng H, Fukuyama S, Egawa S, et al. Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. Pancreas 2005; 30:248-53. [More details]

  56. Maeda K, Hirota M, Kimura Y, Ichihara A, Ohmuraya M, Sugita H, Ogawa M. Proinflammatory role of trypsin and protease-activated receptor-2 in a rat model of acute pancreatitis. Pancreas 2005; 31:54-62. [More details]

  57. Ma T, Kang C, Shao H, Qi Q, Hu W. Protective effects of ulinastatin on proliferation and cytokine release of splenocytes from rats with severe acute pancreatitis. Eur Surg Res 2006; 38:445-50. [More details]

  58. Shi C, Zhao X, Wang X, Zhao L, Andersson R. Potential effects of PKC or protease inhibitors on acute pancreatitis-induced tissue injury in rats. Vascul Pharmacol 2007; 46:406-11. [More details]

  59. Kitagawa M, Hayakawa T. Antiproteases in the treatment of acute pancreatitis. JOP. J Pancreas (Online) 2007; 8:518-25. [More details]

Keywords Aprotinin; Cytokines; Gabexate; nafamostat; Pancreatitis; Protease Inhibitors; urinastatin

Correspondence Chun-Chia Chen: chencc@vghtpe.gov.tw

JOP Home page